Previously, the cyclophilin inhibitors cyclosporin A (CsA) and Alisporivir (ALV) were shown to 26 inhibit the replication of diverse RNA viruses, including arteriviruses and coronaviruses, which both 27 belong to the order Nidovirales. Here we aimed to identify arterivirus proteins involved in the mode-28 of-action of cyclophilin inhibitors and to investigate how these compounds inhibit arterivirus RNA 29 synthesis in the infected cell. Repeated passaging of the arterivirus prototype equine arteritis virus 30 (EAV) in the presence of CsA revealed that reduced drug sensitivity is associated with the emergence 31 of adaptive mutations in nonstructural protein 5 (nsp5), one of the transmembrane subunits of the 32 arterivirus replicase polyprotein. Introduction of singular nsp5 mutations (nsp5 Q21R, Y113H, or 33 A134V) led to a ~2-fold decrease in sensitivity to CsA treatment, whereas combinations of mutations 34 further increased EAV's CsA resistance. The detailed experimental characterization of engineered 35 EAV mutants harboring CsA-resistance mutations implicated nsp5 in arterivirus RNA synthesis. 36
Abstract 25
Previously, the cyclophilin inhibitors cyclosporin A (CsA) and Alisporivir (ALV) were shown to 26 inhibit the replication of diverse RNA viruses, including arteriviruses and coronaviruses, which both 27 belong to the order Nidovirales. Here we aimed to identify arterivirus proteins involved in the mode-28 of-action of cyclophilin inhibitors and to investigate how these compounds inhibit arterivirus RNA 29 synthesis in the infected cell. Repeated passaging of the arterivirus prototype equine arteritis virus 30 (EAV) in the presence of CsA revealed that reduced drug sensitivity is associated with the emergence 31 of adaptive mutations in nonstructural protein 5 (nsp5), one of the transmembrane subunits of the 32 arterivirus replicase polyprotein. Introduction of singular nsp5 mutations (nsp5 Q21R, Y113H, or 33 A134V) led to a ~2-fold decrease in sensitivity to CsA treatment, whereas combinations of mutations 34 further increased EAV's CsA resistance. The detailed experimental characterization of engineered 35 EAV mutants harboring CsA-resistance mutations implicated nsp5 in arterivirus RNA synthesis. 36
Particularly, in an in vitro assay, EAV RNA synthesis was far less sensitive to CsA treatment when 37 nsp5 contained the adaptive mutations mentioned above. Interestingly, for increased sensitivity to the 38 closely-related drug ALV CsA-resistant nsp5 mutants required the incorporation of an additional 39 adaptive mutation, which resided in nsp2 (H114R), another transmembrane subunit of the arterivirus 40 replicase. Our study provides the first evidence for the involvement of nsp2 and nsp5 in the 41 mechanism underlying the inhibition of arterivirus replication by cyclophilin inhibitors. 42 43 44 Importance 45 Currently, no approved treatments are available to combat infections with nidoviruses, a group of plus-46 stranded RNA viruses including important zoonotic and veterinary pathogens. Previously, the 47 cyclophilin inhibitors cyclosporin A (CsA) and Alisporivir (ALV) were shown to inhibit the 48 replication of diverse nidoviruses (both arteriviruses and coronaviruses), and may thus represent a 49 class of pan-nidovirus inhibitors. Here, using the arterivirus prototype equine arteritis virus, we have 50 established that resistance to CsA and ALV treatment is associated with adaptive mutations in two 51 trans-membrane subunits of the viral replication complex, nonstructural proteins 2 and 5. This is the 52 first evidence for the involvement of specific replicase subunits of nidoviruses in the mechanism 53 underlying the inhibition of their replication by cyclophilin inhibitors. Understanding this mechanism 54 of action is of major importance to guide future drug design, both for nidoviruses and other RNA 55 viruses inhibited by these compounds. 56 57 Introduction 58 Equine arteritis virus (EAV) is a positive-strand RNA (+RNA) virus that belongs to the 59 arterivirus family in the order Nidovirales, a steadily expanding clade of positive-stranded RNA 60 (+RNA) viruses that also includes the roni-, mesoni-, and coronavirus families 61 (https://talk.ictvonline.org/ictv-reports/ictv_9th_report/positive-sense-rna-viruses-62 2011/w/posrna_viruses/219/nidovirales). The latter group includes the zoonotic severe acute 63 respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome (MERS)-CoV, 64 which can cause lethal respiratory infections in humans (reviewed by (Cui et al., 2018; de Wit et al., 65 2016) ). Furthermore, the nidovirus order includes several important veterinary pathogens, such as 66 avian, porcine, and bovine coronaviruses, and the arterivirus porcine reproductive and respiratory 67 syndrome virus (PRRSV). The latter continues to cause major economic losses in the swine industry 68 worldwide (Holtkamp et al., 2013) . Despite extensive efforts during recent years, currently no 69 approved treatments to combat nidovirus infections are available. 70
Equine arteritis virus (EAV) is the prototype of the arterivirus family and has a genome size of 71 12.7 kilobases (kb) . About three-quarters of its polycistronic genome is occupied 72 by the viral replicase gene, which is expressed as two polyproteins (pp), pp1a and the C-terminally 73 extended pp1ab, with the synthesis of the latter depending on a programmed ribosomal frameshift that 74 can occur just upstream of the ORF1a stop codon. The post-translational maturation of pp1a and 75 pp1ab ( Fig. 1A) involves extensive proteolytic cleavage (into at least 13 non-structural proteins (nsps)) 76 by viral proteases residing in nsp1 (PLP1), nsp2 (PLP2), and nsp4 (M pro ). In the cytoplasm of 77 arterivirus-infected cells, most of the viral nsps and viral RNA synthesis are associated with 78 membranous 'replication organelles' (ROs) that typically include paired membranes and double-79 membrane vesicles (DMVs; (Knoops et al., 2012; Zhang et al., 2018) , and reviewed by (van der 80 Hoeven et al., 2016)). Co-expression of the nsp2 and nsp3 transmembrane subunits of the EAV 81 replicase induces the formation of similar double-membrane structures (Snijder et al., 2001) . Recently, 82 a role in modulating RO membrane curvature and DMV formation was proposed for the third 83 transmembrane replicase subunit, nsp5 (van der Hoeven et al., 2016). The core of the arteriviral RNA-84 synthesizing machinery, sometimes also referred to as replication and transcription complex (RTC), is 85 formed by ORF1b-encoded nsps like nsp9 and nsp10, which include the RNA-dependent RNA-86 polymerase (RdRp) and helicase (Hel) domains, respectively. In addition, host factors appear to be 87 required to promote efficient viral RNA synthesis (van Hemert et al., 2008) . The RTC directs viral 88 genome replication as well as the synthesis of a nested set of subgenomic (sg) mRNAs that is used to 89 express the genes encoding the viral structural proteins, which are located in the 3'-proximal quarter of 90 the genome (reviewed in 2005)). However, CsA also has immune-suppressive properties (Schreiber and Crabtree, 1992) that 99 would constitute a highly undesirable side-effect in the context of antiviral therapy. Therefore, 100 numerous non-immunosuppressive Cyp inhibitors have been developed. One of these, Alisporivir 101 (ALV) has been identified as a potent inhibitor of hepatitis C virus (HCV) and other RNA viruses 102 (reviewed in (de Wilde et al., 2018a; Naoumov, 2014)). Previously, we showed that also nidovirus 103 replication is sensitive to ALV treatment, using drug concentrations comparable to the EC50 previously 104 determined for CsA (de Wilde et al., 2017). 105
The most ubiquitously expressed member of the Cyp family is the cytosolic CypA, which has 106 been proven to be an essential host factor in the replication of e.g. hepatitis C virus (HCV), human 107 immunodeficiency virus 1 (HIV-1), West Nile virus (reviewed in (Frausto et al., 2013) Our present study aimed to investigate the molecular details of the inhibition of arterivirus 114 replication by cyclophilin inhibitors. To this end, we first passaged EAV in the presence of inhibitory 115
CsA concentrations, to induce resistance to the compound. Subsequently, adaptive mutations that 116 markedly decreased the sensitivity of EAV replication to CsA treatment were found to map to nsp5, 117 one of the transmembrane subunits of the arterivirus replicase. We could show that CsA treatment 118 interferes with EAV RNA synthesis, and that the CsA-resistance mutations in nsp5 render replication, 119 and in particular RNA synthesis, less sensitive to CsA treatment. Furthermore, we show that resistance 120 to the closely related Cyp inhibitor ALV requires an additional adaptive mutation in nsp2, a second 121 transmembrane subunit of the arterivirus replicase that is essential for both polyprotein processing and 122 RO formation. Our studies implicate both nsp2 and nsp5 in the mechanism underlying the sensitivity 123 of arterivirus replication to cyclophilin inhibitor treatment. Moreover, they suggest that the role of 124 cyclophilins as arterivirus host factors is specifically linked to viral RNA synthesis, possibly through 125 interactions with key players in RO formation. were determined by plaque assay on BHK-21 cells (Nedialkova et al., 2010) . Huh7 cells lacking CypA 135 expression (Huh7-CypA KO cells), generated by transfection with a pLentiCRISPR v2 plasmid and a 136
CypA-specific guide RNA, were described previously (de Wilde et al., 2018b). 137
138
Isolation of drug-resistant EAV mutants. To obtain CsA-or ALV-resistant mutants, EAV was 139 passaged (MOI 0.005) in Huh7 cells in the presence of increasing compound concentrations (4 to 20 140 µM for CsA, 4 to 75 µM for ALV). For CsA, passaging was repeated independently three times, 141 resulting in EAV lineages CsA-1, CsA-2, and CsA-3. For ALV, two independent ALV-resistant 142 lineages (EAV ALV-1 and ALV-2) were obtained. A control lineage (EAVwt), passaged in the 143 absence of CsA or ALV, was generated in parallel to screen for adaptive mutations unrelated to drug 144 treatment, which might arise during cell culture passaging of EAV. CsA or ALV concentrations were 145 increased in the following passage at the moment that in drug-treated, EAV-infected cells, virus-146 induced CPE appeared at the same moment as in the control-passaged EAV lineage, indicating that 147 virus replication is not affected by that particular drug concentration. Drug-specific toxicity was 148 monitored in cells that were left uninfected. Resistance to CsA or ALV was monitored using the cell-149 based antiviral screening assay described below. and plaque assays (data not shown). In vitro transcribed RNA derived from wt or mutant pEAN900 181 was electroporated into BHK-21 cells using Amaxa Nucleofector technology (Lonza), as described 182 previously (Beerens and Snijder, 2007) 2013a). We now aimed to investigate the mechanism-of-action by which arterivirus infection is 232 inhibited in the presence of this cyclophilin inhibitor. To this end, wt EAV (strain Bucyrus; MOI 233 0.005) was serially passaged in Huh7 cells in the presence of increasing concentrations of CsA (4 to 234 20 µM). Three independent virus lineages were generated (named EAV CsA-1 to -3), which exhibited 235 clearly decreasing sensitivity to CsA ( Fig. 2A ). By passage 7 (P7), all three lineages replicated in the 236 presence of 20 µM CsA (data not shown), a dose that is approximately 10-fold higher than the EC50 237 value observed when using wtEAV ( Table 1 ). Of note, additional passaging (up to passage 9) did not decrease CsA 249 sensitivity any further. 250
Next, we confirmed the reduced CsA sensitivity of CsA-1 to -3 P7 virus by infecting (MOI 251 0.01) Huh7 or BHK-21 cells in the presence of 4 µM CsA, a dose that fully inhibits wtEAV 252 replication. Virus production was measured at 48 h p.i., which confirmed that wtEAV-P7 infection in 253 the presence of 4 µM CsA indeed did not yield detectable virus progeny ( Fig. 2C ). At the same CsA 254 concentration, titers of above 10 4 PFU/ml (EAV CsA-1 and CsA-3) or even around 10 6 PFU/ml (EAV 255 CsA-2) were reached when infection was done with the P7 viruses from the three CsA-resistant 256 lineages. Similar results were obtained in BHK-21 cells, albeit that the yields of all three lineages were 257 equally reduced compared to wtEAV-P7 in this cell line (data not shown). 258
259
Most CsA resistance-associated mutations map to EAV nsp5. In order to identify CsA resistance-260 associated mutations, the consensus genome sequence of the three P7 CsA-resistant EAV samples was 261 determined following RT-PCR amplification ( Table 2 and Fig. 1A ). The EAV CsA-1 consensus 262 sequence contained three mutations, all mapping to the nsp5-coding region of ORF1a and resulting in 263 three amino acids substitutions: Q21R (mixed with the wt sequence), Y113H, and A134V. 264
Remarkably, the Y113H mutation in nsp5 was also encoded by the ORF1a consensus sequence of the 265 EAV CsA-2 population, but now accompanied by a mutation in the 5' untranslated region (5'-UTR) 266
(A43G) and one in ORF1b, specifying a mutation in the nsp10 helicase domain (Y387H). Lineage 267
CsA-3 contained mutations leading to substitutions in nsp2 (A199T) and again nsp5 (L8S and Q21R). 268
None of the consensus sequences contained any synonymous mutations that had been fixed during 269 passaging. Likewise, no mutations were discovered in the consensus sequence of the wtEAV-P7 270 control, implying that the mutations identified in the CsA-1 to -3 P7 viruses potentially are linked to 271 the established reduced sensitivity to CsA. 272
To assess the importance of the identified mutations for CsA sensitivity, each mutation was 273 individually reverse engineered into the EAV genome, using full-length cDNA clone pEAN900. 274
Recombinant mutant viruses were launched and their CsA sensitivity was assayed in Huh7 cells using 275 the CPE-based assay outlined above (see Fig. 1b ). Interestingly, three of the nsp5 mutations (Q21R, 276 Y113H, and A134V) decreased the CsA sensitivity of EAV replication (EC50 values of ~4.4 µM vs. 277 1.6 µM for the wt control (rEAV wt )). No change in sensitivity was observed for any of the other 278 mutations (see Table 1 and sFig. 1A-H). Of note, the nsp5 L8S mutation reverted back to the wild-type 279 residue (data not shown), which likely explains the marginal decrease in CsA sensitivity observed in 280 this assay (sFig. 1C). 281
The increase in CsA resistance observed for the recombinant mutant viruses with singular 282 mutations appeared to be ~3-fold smaller than the approximately 5-fold increase observed for the P7 283
CsA-1 to -3 viruses, which each carried multiple substitutions. Therefore, we also engineered mutant 284 viruses with genome sequences identical to the consensus sequence of these three CsA-resistant virus 285 lineages. For lineage CsA-1, which contained a mix of Q (wt) and R (mutant) at residue 21 of nsp5, 286
both variants were engineered and tested. Compared to the viruses carrying singular mutations, mutant 287 rEAV nsp5 Y113H+A134V displayed a decreased sensitivity to CsA, which now approached that of the 288 EAV CsA-1 lineage ( Fig. 3A and Table 1 ). When the Q21R mutation was added, the CsA resistance 289 diminished slightly compared to the Y113H+A134V double mutant ( Fig. 3B and Table 1 ; EC50 of 9.1 290 vs. 7.2 µM). However, upon passaging and resequencing (data not shown), the double mutant 291 appeared to be genetically instable, which may also explain the mixed sequence found at nsp5 codon 292 21 in the lineage CsA-1 consensus sequence. For lineage CsA-2, combining the three mutations (in 5'-293 UTR, nsp5, and nsp10) into the same genome did not further improve CsA resistance compared to 294 rEAV nsp5 Y113H (Fig. 3C ). This lack of a synergistic effect indicates that the mutations in 5'-UTR and 295 nsp10 do not contribute substantially to the level of CsA resistance of CsA-2. In the case of EAV 296
CsA-3, combining nsp5 L8S , but not nsp2 A199T , with nsp5 Q21R yielded a ~2-fold further decrease in CsA 297 sensitivity (EC50 value of 9.1 µM; compare sFigs. 1B, E and Fig. 3D and see Table 1 ) suggesting that 298 the nsp2 A199T mutation does not contribute to CsA resistance. 299
Overall, the above results clearly implicated various EAV nsp5 mutations in reduced CsA sensitivity. 300 Whereas combining nsp5 mutations increased CsA resistance compared to singular nsp5 mutants, the 301 substitutions in 5'-UTR, nsp2, and nsp10 did not contribute detectably to CsA resistance. CsA-1 302 mutant rEAV nsp5 Q21R+Y113H+A134V was selected for follow-up experiments, as it was genetically stable 303 upon passaging (data not shown) and included the single nsp5 mutation (Y113H) that was key to the 304 CsA resistance of lineage CsA-2. For simplicity, this mutant will be referred to as rEAV QYA from this 305 point forward. 5C) did not reveal obvious differences in DMV amounts, size, or ultrastructure. As replication of 329 rEAV QYA in the presence of CsA was delayed compared to the replication in untreated cells, we 330 analyzed cells infected with this mutant at 14 h p.i (Fig. 4 ). In the presence of CsA, no DMVs were 331 observed for rEAV wt (Fig. 5E ), while the morphology and size of the DMVs in rEAV QYA -infected cells 332 were similar to the structures observed upon infection of untreated cells infected with rEAV wt -or 333 rEAV QYA (Fig. 5F ). Notably, severe compound-induced dilation of ER membranes was observed, a 334 phenomenon that was independent of EAV infection as it was also observed in CsA-treated mock-335 infected Huh7 cells (compare Figs. 5A-C and 5D-F). Taken together, these observations strongly 336 suggest that CsA treatment interferes with a very early stage of arterivirus infection, i.e. prior to or 337 during RO formation. Apparently, adaptive mutations in nsp5 can compensate for the detrimental 338 effects of CsA treatment, which may either target one of the viral players directly or affect a host 339 factor involved in arterivirus replication, like cyclophilin A (see above). 340 341 rEAV QYA replication continues to depend on CypA. We previously showed that EAV replication 342 For this purpose, BHK-21 cells were infected with rEAV wt or rEAV QYA and viral RNA synthesis was 355 assayed by metabolic labelling with [ 3 H]uridine from 6.5 to 7.5 h p.i. (Fig. 7A, B ). Cells were also 356 treated with dactinomycin to block cellular transcription. [ 3 H]-uridine incorporation into viral RNA 357 was quantified by isolation of intracellular RNA and liquid scintillation counting (Fig. 7A ). Labeled 358 viral RNA was also visualized by agarose gel electrophoresis and fluorography (Fig. 7B ). This 359 revealed that RNA synthesis by the mutant virus was approximately 40% of wt virus activity, which is 360 in line with the observed delayed growth kinetics and reduced titers of the mutant. However, in the 361 presence of 8 µM of CsA (which was added 1 h prior to the pulse labeling), rEAV wt RNA synthesis 362 was completely blocked, while rEAV QYA RNA synthesis was hardly affected, as evident from both the 363 overall quantification of 3 H-labeled RNA and the RNA analysis using agarose gel electrophoresis ( Fig.  364   7A-B) . experiments suggested that -compared to genome replication -sg RNA synthesis is more impaired 376 for the rEAV QYA mutant (Fig 7B, lane 1 and 3; Fig. 7C, lane 1 and 7) . However, when rEAV wt and 377 rEAV QYA RNA (isolated from infected BHK-21 cells at 7.5 h p.i.) was subjected to direct 378 hybridization analysis using a [ 32 P]-labeled probe that recognizes all EAV mRNAs, an overall 379 decrease in the amount of mutant viral RNAs was visible, but no clear difference in the ratio between 380 the individual sg RNAs and genomic RNA (sFig. 2). Therefore, we concluded that the absence of the 381 sg RNAs in some of the panels presented in Fig. 7 must have been due to the limited sensitivity of 382 these particular assays rather than a specific impairment of sg RNA synthesis. treatment option for chronic HCV infection (Naoumov, 2014) . ALV lacks the immunosuppressive 390 properties of CsA, while retaining a high affinity for cyclophilins. We now established that ALV is 391 able to block also the replication of wtEAV with an EC50 value of 4.5 ± 0.2 µM, an efficiency that is 392 comparable to that observed for CsA (Table 3) . 393
To explore the development of ALV resistance in EAV, two independent passaging 394 experiments in Huh7 cells were performed (EAV ALV-1 and ALV-2) in the presence of increasing 395 ALV concentrations (from 4 µM in passage 1 to 75 µM in passage 10), similar to the approach used to 396 generate CsA-resistant viruses (Fig. 2) . By passage 10, a CPE-based assay revealed that, compared to 397 the wtEAV-P10, the sensitivity to ALV was reduced by 7.4-and 2.8-fold for EAV lineages ALV-1 398 and ALV-2, respectively ( Fig. 8A and Table 3 ). Interestingly, the P10 samples of EAV lineages ALV-399 1 and -2 were ~4-fold less sensitive to CsA as well ( Fig. 8B) . Analysis of the ALV-1 and -2 P10 400 consensus sequences revealed that each population contained multiple mutations (Table 2) . These 401 included singular mutations in the 5'-UTR, in ORF1a (nsp1 region), and in the structural protein-402 coding region. Strikingly, the P10 viruses from both lineages also carried two substitutions in nsp5. 403
The two nsp5 mutations in ALV-1 (Y113H and A134V) had previously been identified in lineage 404
CsA-1 (see above), whereas ALV-2 also contained a mutation present in CsA-1, Q21R. Strikingly, 405 both ALV-resistant lineages contained the same mutation (H114R) within the papainlike protease 406 (PLP2) domain of nsp2. We reverse engineered the ALV-1 and -2 mutations into the viral genome, 407 and assayed ALV sensitivity of the mutant viruses. Singular nsp2 and nsp5 mutants displayed a 408 reduced ALV sensitivity, but only the nsp5 mutants were also less sensitive to CsA (Fig. 9 , Table 3 ). 409
Subsequently, combining nsp5 and nsp2 mutations had a synergistic effect and confirmed the 410 importance of the common nsp2 H114R substitution for ALV resistance. Mutations in the 5'UTR and 411 nsp1 did not further reduce the sensitivity to ALV (data not shown), nor did the mutations in the 412 structural protein-coding region contribute to ALV resistance ( Fig. 9 ; Table 3 ). 413
Finally, to further corroborate the importance of nsp2 H114R for ALV resistance, this mutation 414 was transferred to the rEAV QYA triple mutant already carrying the nsp5 mutations identified in our 415 studies into CsA resistance (see above). As anticipated, while the triple mutant was marginally 416 resistant to ALV (most likely due to the presence of the nsp5 A134V mutation, see Fig. 9A ), the addition 417 of nsp2 H114R rendered the rEAV QYA virus nearly insensitive to ALV treatment, while also retaining its 418 reduced CsA sensitivity (Fig. 10) . These results clearly confirmed that the highest level of ALV 419 resistance is achieved by introducing a combination of adaptive mutations in EAV nsp2 and nsp5. 420 421 422 423
Discussion

424
This study demonstrates that adaptive mutations in the transmembrane replicase subunit nsp5 can 425 reduce the sensitivity of EAV replication to CsA treatment. Independently, experiments using the CsA 426 analog ALV pointed in the same direction, in addition to implicating nsp2 in ALV sensitivity and 427 resistance. Substitutions in nsp5 and nsp2 enable EAV to tolerate CsA or ALV concentrations that 428 would normally block virus replication (Figs. 2, 9 and 10) . The largest EC50 increase, about 5-fold, 429 was achieved when multiple substitutions in nsp5 (and nsp2, in the case of ALV) were combined 430 (Table 1 and 3). We previously showed that CsA inhibits EAV RNA synthesis and hypothesized that 431 this may be the major determinant for its inhibitory effect (de Wilde et al., 2013a). Indeed, a 432 combination of three of the acquired CsA resistance mutations in nsp5 (Q21R, Y113H, and A134V) 433 facilitated a certain level of EAV RNA synthesis in the presence of a CsA dose that blocks wt virus 434 activity. This was observed in both virus-infected cells and an in vitro assay for EAV RNA synthesis 435 ( Fig. 7) . interaction of these compounds with EAV replicase subunits themselves has not been formally 460 excluded. In any case, our EM analysis of CsA-treated, EAV-infected cells, which were devoid of 461 DMVs (Fig. 5) , confirmed that the drug treatment blocks an early and basic step in the viral replicative 462 cycle, and that this block can apparently be circumvented by the acquisition of a few adaptive 463 mutations in nps5. 464
Four substitutions in nsp5 were implicated in CsA resistance (L8S, Q21R, Y113H, and 465 A134V), of which only the L8 residue is conserved among arteriviruses (Fig. 1C) . Interestingly, this 466 residue is also part of a potential CypA binding motif (GPxL, as identified by (Piotukh et al., 2005) ), 467 constituting a potential interaction site between the two proteins. However, during infection, this L8S 468 mutation quickly reverted, and therefore the contribution of the L8S substitution to CsA resistance 469 remains unclear. All other three nsp5 mutations (Q21R, Y113H, and A134V) are present in predicted 470 transmembrane domains (Fig. 1B) , and therefore may not be directly involved in interactions of nsp5 471 with Cyps or other proteins. There is no experimental data available on the membrane topology of 472 nsp5, but upon in silico modeling these nsp5 mutations did not appreciably alter the predicted 473 conformation of the various transmembrane domains (data not shown). In addition, our EM analysis of 474 DMV formation upon rEAV nsp5 QYA infection did not reveal any ultrastructural differences, either in 475 the absence or presence of CsA (Fig 5) . Clearly, more detailed information on the 3D-structure of nsp5 476 is needed to assess the impact of the mutations identified in this study on the protein's conformation(s) 477 and interactions at the molecular level. 478
We previously postulated a role for CypA in EAV RTC formation or function, upon 479 demonstrating the cosedimentation of CypA with EAV RTCs in density gradients. Interestingly, no 480
CypA cosedimentation with RTCs was detected in the presence of CsA (de Wilde et al., 2013a). 481
Unfortunately, co-immunoprecipitation experiments using lysates from either ectopic expression of 482 the EAV nsp2-7 polyprotein in 293T cells or EAV-infected cells, could not confirm an interaction 483 between nsp5 and CsA, even when using mild conditions for cell lysis and immunoprecipitation (data 484 not shown). This could obviously be due to technical reasons, e.g. the interaction being very weak or 485 short-lived but an alternative explanation may be that the interaction of CypA with the EAV RTC is 486 not directly via nsp5, or that it depends on factors that were lacking in our assays. 487
Although a direct interaction between an EAV nsp and CypA could not be established, 488 efficient EAV replication is dependent on the presence of CypA, as it is severely reduced in cells 489 depleted for CypA ( Fig 6; ( In analogy with these data, all relevant adaptive mutations in EAV nsp5 map inside the first and last of 502 its four (predicted) transmembrane domains. One possible mechanism is that the adaptive nsp5 503 mutations somehow increase the stability of RTC complexes and thereby counteract the destabilization 504 that may result from CsA penetrating lipid membranes. It has been shown that CsA can be inserted 505 into and destabilize membrane structures, with a preference for sphingomyelin-rich membranes 506 Interestingly, despite the fact that CsA and ALV both are cyclophilin inhibitors, EAV 516 resistance to ALV requires an additional mutation in the nsp2 protease domain PLP2: H114R (Fig 10) . well plates were infected with rEAV wt (control, black line) and the rEAV mutants rEAV-nsp2 H114R 807 (blue), rEAV QYA (red) and rEAV QYA -nsp2 H114R (green) in the presence of 0 to 50 µM ALV (A) or CsA 808 (B). Cells were incubated for three days and cell viability was monitored using a commercial assay. In 809 addition, the cytotoxicity of ALV or CsA treatment only was monitored in parallel in mock-infected 810
Huh7 cells (light grey line). Graphs show the results (average and SD) of a representative experiment 811 that was performed in quadruplicate. All experiments were repeated at least twice. 812 813 sFig. 1. CsA-resistance analysis of rEAV mutants harboring singular mutations identified in the 814 consensus sequences of CsA-1, -2, and -3. rEAV mutants with each of the individual mutations 815 identified in the CsA-1, -2, and -3 consensus sequences were engineered and tested in a CPE-based 816 assay. Huh7 cells in 96-well plates were infected (MOI 0.05) with rEAV wt (control, black line) and 817 rEAV CsA mutants (red line). Cells were incubated for three days in the presence of 0 to 50 µM CsA 818 and cell viability was monitored using a commercial cell viability assay. The cytotoxicity of CsA 819 treatment only was monitored in parallel in mock-infected Huh7 cells (light grey line). Above each 820 panel, the EC50 value of CsA inhibition is indicated (see also Table 1) 
